Similarly, 70% cases of low-grade ovarian carcinomas harbour KRAS or BRAF mutations, leading invariably to constitutive activation of MEK/ERK59, while less than 1% of HGSC exhibit such mutations4, 12. This evidence concerns the gene BRAF and ovarian carcinoma.